Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinteng Huoxue Runji is a topical traditional Chinese medicine (TCM) ointment developed as part of the "Qinteng Huoxue prescription series" by Professor Sun Liyun. It is formulated using a chitosan nanocrystalline drug delivery system to enhance skin penetration and therapeutic efficacy. The ointment is designed for the treatment of psoriasis with blood stasis syndrome, a TCM diagnostic subtype of psoriasis. Its mechanism involves promoting blood circulation and alleviating symptoms associated with blood stasis in the context of TCM theory. The product has been observed to be effective in clinical practice for psoriasis but is currently being evaluated in multicenter, randomized controlled clinical trials for efficacy and safety[1][2][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qinteng huoxue runji.